April 2, 2012
Announcement regarding the Filing in Japan of
an Application for Marketing Approval of KW-6002 for
Parkinson's Disease Treatment
Tokyo, Japan, April 2, 2012 --- Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") announces that it will submit on the application in Japan for the marketing approval of KW-6002 (Istradefylline), which is currently undergoing development for the treatment of Parkinson's disease, has been submitted on March 30, 2012.
KW-6002 is a selective antagonist of adenosine A2A receptors. Kyowa Hakko Kirin has been developing KW-6002 as anti-Parkinson's disease drug with a novel mechanism of action. The outcomes from Japanese clinical trials conducted so far have demonstrated the efficacy and tolerability of KW-6002 in Parkinson's disease patients receiving levodopa therapy.
Kyowa Hakko Kirin believes that KW-6002 provides a new treatment option that is potentially useful in the treatment of Parkinson's disease.